Terms: = Kidney tumors AND SERPINE1, PAI, PAI-1, PAI1, PLANH1 AND Clinical Outcome
3 results:
1. Vascular endothelial profilin-1 drives a protumorigenic tumor microenvironment and tumor progression in renal cancer.
Gau D; Daoud A; Allen A; Joy M; Sagan A; Lee S; Lucas PC; Duensing S; Boone D; Osmanbeyoglu HU; Roy P
J Biol Chem; 2023 Aug; 299(8):105044. PubMed ID: 37451478
[TBL] [Abstract] [Full Text] [Related]
2. Type 1 plasminogen activator inhibitor (pai-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy.
Zubac DP; Wentzel-Larsen T; Seidal T; Bostad L
BMC Urol; 2010 Dec; 10():20. PubMed ID: 21129210
[TBL] [Abstract] [Full Text] [Related]
3. clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
Hofmann R; Lehmer A; Buresch M; Hartung R; Ulm K
Cancer; 1996 Aug; 78(3):487-92. PubMed ID: 8697395
[TBL] [Abstract] [Full Text] [Related]
